Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert S. Langer, Sc.D.

Co-Author

This page shows the publications co-authored by Robert Langer and Omid Farokhzad.
Connection Strength

9.367
  1. Impact of nanotechnology on drug delivery. ACS Nano. 2009 Jan 27; 3(1):16-20.
    View in: PubMed
    Score: 0.413
  2. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev. 2006 Dec 01; 58(14):1456-9.
    View in: PubMed
    Score: 0.354
  3. Drug delivery systems in urology--getting "smarter". Urology. 2006 Sep; 68(3):463-9.
    View in: PubMed
    Score: 0.350
  4. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv. 2006 May; 3(3):311-24.
    View in: PubMed
    Score: 0.342
  5. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006 Apr 18; 103(16):6315-20.
    View in: PubMed
    Score: 0.340
  6. Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem. 2005 Sep 01; 77(17):5453-9.
    View in: PubMed
    Score: 0.327
  7. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004 Nov 01; 64(21):7668-72.
    View in: PubMed
    Score: 0.308
  8. Analysis of the Human Plasma Proteome Using Multi-Nanoparticle Protein Corona for Detection of Alzheimer's Disease. Adv Healthc Mater. 2021 01; 10(2):e2000948.
    View in: PubMed
    Score: 0.234
  9. Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona. Nat Commun. 2020 07 22; 11(1):3662.
    View in: PubMed
    Score: 0.229
  10. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nat Commun. 2017 10 03; 8(1):777.
    View in: PubMed
    Score: 0.189
  11. Multiscale technologies for treatment of ischemic cardiomyopathy. Nat Nanotechnol. 2017 09 06; 12(9):845-855.
    View in: PubMed
    Score: 0.188
  12. Evolution of macromolecular complexity in drug delivery systems. Nat Rev Chem. 2017 Aug; 1(8).
    View in: PubMed
    Score: 0.187
  13. Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles. Proc Natl Acad Sci U S A. 2016 May 17; 113(20):5552-7.
    View in: PubMed
    Score: 0.171
  14. Nanomedicines for Endothelial Disorders. Nano Today. 2015 Dec 01; 10(6):759-776.
    View in: PubMed
    Score: 0.166
  15. Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer. ACS Nano. 2014 Jun 24; 8(6):6056-65.
    View in: PubMed
    Score: 0.150
  16. Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1078-83.
    View in: PubMed
    Score: 0.146
  17. Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med. 2013 Nov 27; 5(213):213ra167.
    View in: PubMed
    Score: 0.144
  18. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A. 2013 Nov 12; 110(46):18638-43.
    View in: PubMed
    Score: 0.144
  19. Correction to Mass Production and Size Control of Lipid-Polymer Hybrid Nanoparticles through Controlled Microvortices. Nano Lett. 2013 Oct 9; 13(10):4997.
    View in: PubMed
    Score: 0.143
  20. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci U S A. 2013 Apr 16; 110(16):6506-11.
    View in: PubMed
    Score: 0.138
  21. Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond). 2013 May; 8(5):687-98.
    View in: PubMed
    Score: 0.134
  22. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol. 2012 Oct; 7(10):623-9.
    View in: PubMed
    Score: 0.133
  23. Mass production and size control of lipid-polymer hybrid nanoparticles through controlled microvortices. Nano Lett. 2012 Jul 11; 12(7):3587-91.
    View in: PubMed
    Score: 0.131
  24. Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano. 2012 May 22; 6(5):4279-87.
    View in: PubMed
    Score: 0.129
  25. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano. 2012 Jan 24; 6(1):696-704.
    View in: PubMed
    Score: 0.127
  26. In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci U S A. 2011 Nov 29; 108(48):19347-52.
    View in: PubMed
    Score: 0.125
  27. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012; 63:185-98.
    View in: PubMed
    Score: 0.124
  28. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials. 2011 Sep; 32(26):6226-33.
    View in: PubMed
    Score: 0.122
  29. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A. 2010 Oct 19; 107(42):17939-44.
    View in: PubMed
    Score: 0.116
  30. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010 Sep 08; 10(9):3223-30.
    View in: PubMed
    Score: 0.116
  31. Poly(ethylene glycol) with observable shedding. Angew Chem Int Ed Engl. 2010 Sep 03; 49(37):6567-71.
    View in: PubMed
    Score: 0.115
  32. ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine (Lond). 2010 Apr; 5(3):361-8.
    View in: PubMed
    Score: 0.112
  33. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond). 2010 Feb; 5(2):269-85.
    View in: PubMed
    Score: 0.111
  34. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A. 2010 Feb 02; 107(5):2213-8.
    View in: PubMed
    Score: 0.111
  35. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol. 2010; (197):55-86.
    View in: PubMed
    Score: 0.110
  36. Polymeric nanoparticles for drug delivery. Methods Mol Biol. 2010; 624:163-75.
    View in: PubMed
    Score: 0.110
  37. Progress in siRNA delivery using multifunctional nanoparticles. Methods Mol Biol. 2010; 629:53-67.
    View in: PubMed
    Score: 0.110
  38. Multifunctional nanoparticles for prostate cancer therapy. Expert Rev Anticancer Ther. 2009 Feb; 9(2):211-21.
    View in: PubMed
    Score: 0.103
  39. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials. 2009 Apr; 30(12):2231-40.
    View in: PubMed
    Score: 0.103
  40. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol Biol. 2009; 544:589-98.
    View in: PubMed
    Score: 0.103
  41. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009 Mar; 30(8):1627-34.
    View in: PubMed
    Score: 0.103
  42. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem. 2008 Sep; 3(9):1311-5.
    View in: PubMed
    Score: 0.101
  43. Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008 Aug; 2(8):1696-702.
    View in: PubMed
    Score: 0.100
  44. Microfluidic platform for controlled synthesis of polymeric nanoparticles. . 2008 Sep; 8(9):2906-12.
    View in: PubMed
    Score: 0.100
  45. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008 Aug; 26(8):442-9.
    View in: PubMed
    Score: 0.099
  46. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008 Feb 19; 105(7):2586-91.
    View in: PubMed
    Score: 0.097
  47. New frontiers in nanotechnology for cancer treatment. Urol Oncol. 2008 Jan-Feb; 26(1):74-85.
    View in: PubMed
    Score: 0.096
  48. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007 Dec; 2(12):751-60.
    View in: PubMed
    Score: 0.095
  49. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008 May; 83(5):761-9.
    View in: PubMed
    Score: 0.095
  50. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond). 2007 Oct; 2(5):669-80.
    View in: PubMed
    Score: 0.094
  51. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. . 2007 Oct; 7(10):3065-70.
    View in: PubMed
    Score: 0.094
  52. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem. 2007 Sep; 2(9):1268-71.
    View in: PubMed
    Score: 0.094
  53. Nanofabrication and microfabrication of functional materials for tissue engineering. Tissue Eng. 2007 Aug; 13(8):1867-77.
    View in: PubMed
    Score: 0.093
  54. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007 Feb; 28(5):869-76.
    View in: PubMed
    Score: 0.088
  55. Magnetically responsive polymeric microparticles for oral delivery of protein drugs. Pharm Res. 2006 Mar; 23(3):557-64.
    View in: PubMed
    Score: 0.084
  56. Micropatterned cell co-cultures using layer-by-layer deposition of extracellular matrix components. Biomaterials. 2006 Mar; 27(8):1479-86.
    View in: PubMed
    Score: 0.082
  57. Cell docking inside microwells within reversibly sealed microfluidic channels for fabricating multiphenotype cell arrays. Lab Chip. 2005 Dec; 5(12):1380-6.
    View in: PubMed
    Score: 0.082
  58. A materials-science perspective on tackling COVID-19. Nat Rev Mater. 2020 Oct 14; 1-14.
    View in: PubMed
    Score: 0.058
  59. Author Correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2018 Dec; 2(12):968.
    View in: PubMed
    Score: 0.051
  60. Drug loading augmentation in polymeric nanoparticles using a coaxial turbulent jet mixer: Yong investigator perspective. J Colloid Interface Sci. 2019 Mar 07; 538:45-50.
    View in: PubMed
    Score: 0.051
  61. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2018 11; 2(11):850-864.
    View in: PubMed
    Score: 0.050
  62. VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science. 2015 Jun 19; 348(6241):aaa8205.
    View in: PubMed
    Score: 0.040
  63. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci U S A. 2015 Jan 13; 112(2):E156-65.
    View in: PubMed
    Score: 0.039
  64. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine. 2014 May 19; 32(24):2882-95.
    View in: PubMed
    Score: 0.037
  65. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano. 2013 Dec 23; 7(12):10671-80.
    View in: PubMed
    Score: 0.036
  66. Synthesis and in vitro evaluation of a multifunctional and surface-switchable nanoemulsion platform. Chem Commun (Camb). 2013 Oct 21; 49(82):9392-4.
    View in: PubMed
    Score: 0.036
  67. Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano. 2013 Nov 26; 7(11):9975-83.
    View in: PubMed
    Score: 0.036
  68. Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy. Bioconjug Chem. 2013 Sep 18; 24(9):1429-34.
    View in: PubMed
    Score: 0.035
  69. Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study. Nanomedicine. 2014 Feb; 10(2):401-9.
    View in: PubMed
    Score: 0.035
  70. Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. ACS Nano. 2013 Jul 23; 7(7):5675-83.
    View in: PubMed
    Score: 0.035
  71. Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging. Chem Commun (Camb). 2012 Jun 14; 48(47):5835-7.
    View in: PubMed
    Score: 0.032
  72. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012 Apr 04; 4(128):128ra39.
    View in: PubMed
    Score: 0.032
  73. Synthesis of size-tunable polymeric nanoparticles enabled by 3D hydrodynamic flow focusing in single-layer microchannels. Adv Mater. 2011 Mar 25; 23(12):H79-83.
    View in: PubMed
    Score: 0.030
  74. On firm ground: IP protection of therapeutic nanoparticles. Nat Biotechnol. 2010 Dec; 28(12):1267-70.
    View in: PubMed
    Score: 0.029
  75. Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano. 2010 Mar 23; 4(3):1671-9.
    View in: PubMed
    Score: 0.028
  76. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008 Nov 11; 105(45):17356-61.
    View in: PubMed
    Score: 0.025
  77. The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules. Biomaterials. 2008 Mar; 29(9):1216-23.
    View in: PubMed
    Score: 0.024
  78. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl. 2006 Dec 11; 45(48):8149-52.
    View in: PubMed
    Score: 0.022
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.